Piper Sandler Maintains Overweight on Axsome Therapeutics, Raises Price Target to $113
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and increased the price target from $90 to $113, indicating a positive outlook on the company's stock.
January 16, 2024 | 2:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler's analyst has reaffirmed an Overweight rating on Axsome Therapeutics and raised the price target to $113, suggesting confidence in the company's growth prospects.
The increase in price target by Piper Sandler reflects a strong endorsement of Axsome Therapeutics' potential. This type of analyst rating and price target adjustment can lead to increased investor confidence and a potential short-term rise in the stock price, as market participants may interpret this as a sign of expected future performance and growth.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100